Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 8
1997 10
1998 10
1999 14
2000 5
2001 8
2002 3
2003 3
2004 5
2005 2
2006 2
2007 3
2008 8
2009 6
2010 2
2011 1
2012 1
2013 2
2014 1
2016 1
2017 2
2018 4
2019 1
2020 1
2021 2
2022 4
2023 2
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. Murphy MG, et al. J Clin Endocrinol Metab. 1998 Feb;83(2):320-5. doi: 10.1210/jcem.83.2.4551. J Clin Endocrinol Metab. 1998. PMID: 9467534 Clinical Trial.
MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001). ...Neither the serum cortisol nor t …
MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance respo …
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
Cardaci TD, Machek SB, Wilburn DT, Heileson JL, Harris DR, Cintineo HP, Willoughby DS. Cardaci TD, et al. Exp Physiol. 2022 Dec;107(12):1467-1476. doi: 10.1113/EP090741. Epub 2022 Nov 16. Exp Physiol. 2022. PMID: 36303408 Free article.
A 25-year-old male ingested LGD-4033 (10 mg) and MK-677 (15 mg) daily for 5 weeks. Blood and body composition metrics were obtained pre-, on- and post-cycle. ...These data demonstrate that LGD-4033 and MK-677 increase several body composition parameter …
A 25-year-old male ingested LGD-4033 (10 mg) and MK-677 (15 mg) daily for 5 weeks. Blood and body composition metrics were obt …
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
Lee J, Kwon A, Chae HW, Lee WJ, Kim TH, Kim HS. Lee J, et al. Yonsei Med J. 2018 Dec;59(10):1174-1180. doi: 10.3349/ymj.2018.59.10.1174. Yonsei Med J. 2018. PMID: 30450851 Free PMC article.
This study aimed to investigate the effects of MK-677, an orally active GHS, on somatic growth in rats. MATERIALS AND METHODS: The serum levels of GH were measured after oral administration of MK-677 to confirm GH stimulatory effects. ...However, oral …
This study aimed to investigate the effects of MK-677, an orally active GHS, on somatic growth in rats. MATERIALS AND METHODS: …
Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.
Kintz P, Gheddar L. Kintz P, et al. Clin Chim Acta. 2026 Jan 1;578:120578. doi: 10.1016/j.cca.2025.120578. Epub 2025 Aug 27. Clin Chim Acta. 2026. PMID: 40882886
MATERIAL AND METHOD: A single 10 mg dose of ibutamoren, a growth hormone secretagogue, was administered to a male volunteer and his hair was collected 4 weeks after exposure. ...CONCLUSION: The interpretation of the findings of ibutamoren in human hair can be establ …
MATERIAL AND METHOD: A single 10 mg dose of ibutamoren, a growth hormone secretagogue, was administered to a male volunteer and his h …
The Safety and Efficacy of Growth Hormone Secretagogues.
Sigalos JT, Pastuszak AW. Sigalos JT, et al. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. Sex Med Rev. 2018. PMID: 28400207 Free PMC article. Review.
AIM: To review the literature on GH secretagogues (GHSs), which include GH-releasing peptides and the orally available small-molecule drug ibutamoren mesylate. METHODS: Review of clinical studies on the safety and efficacy of GHSs in human subjects. ...
AIM: To review the literature on GH secretagogues (GHSs), which include GH-releasing peptides and the orally available small-molecule drug …
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.
Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Mathew B, Koshy SA. Philip M, et al. Rapid Commun Mass Spectrom. 2022 Sep 30;36(18):e9337. doi: 10.1002/rcm.9337. Rapid Commun Mass Spectrom. 2022. PMID: 35716382
RESULTS: In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren leads to hydroxylated metabolites (mono and di). ...The major metabolites can be detected up to 96 hours after a single dose, and ibutamoren …
RESULTS: In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren lead …
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Murphy MG, et al. J Bone Miner Res. 1999 Jul;14(7):1182-8. doi: 10.1359/jbmr.1999.14.7.1182. J Bone Miner Res. 1999. PMID: 10404019 Free article. Clinical Trial.
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed …
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial …
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Copinschi G, et al. Neuroendocrinology. 1997 Oct;66(4):278-86. doi: 10.1159/000127249. Neuroendocrinology. 1997. PMID: 9349662 Clinical Trial.

In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a more than 20% increase in REM sleep as compared to placebo (p < 0.05). The frequency of deviations from normal sleep decreased from 42% un

…
In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a m …
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group. Murphy MG, et al. J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25. doi: 10.1210/jcem.86.3.7294. J Clin Endocrinol Metab. 2001. PMID: 11238495 Clinical Trial.

Patients who received MK-677 alone or placebo through month 12 received MK-677 (25 mg) plus alendronate (10 mg) from months 12-18. ...MK-677 plus alendronate increased BMD at the femoral neck (4.2% vs. 2.5% for alendronate; P < 0.05).

…
Patients who received MK-677 alone or placebo through month 12 received MK-677 (25 mg) plus alendronate (10 mg) …
105 results